- Home
- API vs LXEO Comparison
API vs LXEO Comparison
Compare API & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- API
- LXEO
- Stock Information
- Founded
- API 2013
- LXEO 2017
- Country
- API United States
- LXEO United States
- Employees
- API N/A
- LXEO N/A
- Industry
- API Computer Software: Prepackaged Software
- LXEO
- Sector
- API Technology
- LXEO
- Exchange
- API Nasdaq
- LXEO Nasdaq
- Market Cap
- API 342.9M
- LXEO 290.5M
- IPO Year
- API 2020
- LXEO 2023
- Fundamental
- Price
- API $3.83
- LXEO $5.36
- Analyst Decision
- API Strong Buy
- LXEO Strong Buy
- Analyst Count
- API 1
- LXEO 7
- Target Price
- API $6.00
- LXEO $15.29
- AVG Volume (30 Days)
- API 510.0K
- LXEO 421.5K
- Earning Date
- API 08-18-2025
- LXEO 11-12-2025
- Dividend Yield
- API N/A
- LXEO N/A
- EPS Growth
- API N/A
- LXEO N/A
- EPS
- API N/A
- LXEO N/A
- Revenue
- API $133,554,000.00
- LXEO N/A
- Revenue This Year
- API $7.20
- LXEO N/A
- Revenue Next Year
- API $11.26
- LXEO N/A
- P/E Ratio
- API N/A
- LXEO N/A
- Revenue Growth
- API N/A
- LXEO N/A
- 52 Week Low
- API $1.95
- LXEO $1.45
- 52 Week High
- API $6.99
- LXEO $11.72
- Technical
- Relative Strength Index (RSI)
- API 56.15
- LXEO 64.62
- Support Level
- API $3.70
- LXEO $4.90
- Resistance Level
- API $3.96
- LXEO $5.56
- Average True Range (ATR)
- API 0.17
- LXEO 0.30
- MACD
- API 0.04
- LXEO 0.02
- Stochastic Oscillator
- API 81.43
- LXEO 78.26
About API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.